DHANAK DASHYANT (EVP & Chief Scientific Officer) received a stock award from DECIPHERA PHARMACEUTICALS, INC.
Compensation award — not an open‑market transaction. Less informative as a directional signal.
A · 1 award
Filed: 2/20/2024ACC: 0000950170-24-017089
Officer· EVP & Chief Scientific Officer
Since Sep 2023
+86.38K
Net shares
Net buyer
$0.00
Total acquired
0
Open market trades
0B · 0S
2
Total transactions
86.38K acquired
Non-Derivative Transactions1
Common Stock
Direct
Shares
+17.27K
Price / share
—
Trade value
—
% of position
12.3%
2/15/2024
140.90K→158.18K
Total
Net shares
+17.27K
Net value
$0.00
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 2/15/2024 | A · Award | +17.27K | — | — | 12.3% | 140.90K | 158.18K |
| Total | +17.27K | $0.00 | ||||||
Derivative Transactions1
Stock Option (Right to Buy)
Direct
Converts to
Common Stock
69.10K shares
Shares
+69.10K
Strike price
15.92
Held after
69.10K
Exercisable
—
2/15/2024
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) Direct | Common Stock69.10K shares | 2/15/2024 | A · Award | +69.10K | 15.92 | — | 69.10K |